Cookies

Like most websites The Pathologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subspecialties Microbiology and immunology, Oncology, Technology and innovation, Microscopy and imaging, Histology

Computational pathology: A new platform to empower personalized immunotherapy

This webinar is a “must see” for anyone interested in PD-1/PD-L1 targeted immunotherapy and quantitative methods for biomarker assessment in immuno-oncology.

Clinical success of immunotherapy targeting the PD-1/PD-L1 axis has significantly improved the outcome of patients with a broad spectrum of cancer types. However, not all patients respond equally. Improvement in patient stratification is a critical research priority, including A) methodological progress in the assessment of tissue-based predictive biomarkers such as PD-L1 and B) the development of new patient stratification tools using computational pathology methods.

In this webinar, Dr. Viktor Koelzer from the Institute of Cancer and Genomic Science at the University of Birmingham and the Wellcome Trust Centre for Human Genetics at the University of Oxford will discuss these critical areas of improvement within the context of two recent studies published by the presenter and his colleagues.

First, in a study published in Histopathology, a new standardized, digital protocol for the assessment of PD-L1 staining is developed using the HALO® platform developed and the output data and reproducibility is compared to conventional assessment by expert pathologists in melanoma. Computational PD-L1 scores captured the full diagnostic spectrum of PD-L1 expression at single cell resolution, were consistent with the “gold standard” pathologist-based consensus reading and improved inter-observer reproducibility.

In a second landmark study published in Nature Medicine in June 2018, a combination of approaches including the HALO platform is used to characterize a metabolically and transcriptionally-distinct subset of PD1+ TILS (PD-1T) that possess an intrinsically high capacity for tumor recognition. An image analysis protocol to quantify PD-1T cells in tissues is developed and used to demonstrate that the presence of PD-1T cells in tumors is highly predictive for both clinical response and survival in non-small cell lung cancer patients.

By way of introduction, the host, Dr. Kate Tunstall from Indica Labs, will give a brief presentation on the HALO platform and the image analysis modules used in the highlighted studies.

View on demand

Enjoy our FREE content!

Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE and always will be!

Login if you already created an account

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine
Register

Or Login as a Guest or via Social Media

Newsletter

Send me the latest from The Pathologist.

Sign up now

Most Popular

Register here

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register